论文部分内容阅读
微粒化非诺贝特是一种安全有效的降脂药物 ,广泛应用于临床。本文旨在探讨性别差异对其疗效的影响。材料与方法1.病例选择 :81例未进行过降脂治疗的原发性高甘油三酯血症和混合性高脂血症患者 ,其中男 38例、女 4 3例 ,平均年龄分别为 51.6± 12 .0岁和 57.8± 9.8岁。所有病人
Micronized fenofibrate is a safe and effective lipid-lowering drug, widely used in clinical. This article aims to explore the impact of gender differences on its efficacy. Materials and methods 1. Case selection: 81 cases of patients with primary hypertriglyceridemia and mixed hyperlipidemia without lipid-lowering therapy, 38 males and 43 females, the average age were 51.6 ± 12.0 years old and 57.8 ± 9.8 years old. All patients